Search

Your search keyword '"visinin-like protein 1"' showing total 3 results
Start Over Descriptor "visinin-like protein 1" Topic cerebrospinal fluid
3 results on '"visinin-like protein 1"'

1. Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis.

Author

Dulewicz, Maciej, Kulczyńska-Przybik, Agnieszka, Borawska, Renata, Słowik, Agnieszka, and Mroczko, Barbara

Subjects
*ALZHEIMER'S disease, *MILD cognitive impairment, *CEREBROSPINAL fluid, *CEREBROSPINAL fluid examination, *BIOMARKERS, *NEURODEGENERATION, *CELL anatomy
Abstract

Synaptic loss and dysfunction are one of the earliest signs of neurodegeneration associated with cognitive decline in Alzheimer's disease (AD) and other neurodegenerative diseases. This study aimed to assess the relationships between biological processes of the synaptic pathology underlying AD, molecular functions, and dynamics of the change concentrations of selected proteins reflecting synaptic and axonal pathology in dementia stages. Neurogranin (Ng), neuronal pentraxin receptor (NPTXR), and Visinin-like protein 1 (VILIP1) concentrations were measured in the cerebrospinal fluid (CSF) of MCI, AD, and non-demented controls (CTRL) using quantitative immunological methods. Gene ontology (GO) enrichment analysis was used for the functional analysis of tested proteins. The CSF Aβ42/Ng ratio was significantly different between all the compared groups. The CSF NPTXR/Ng ratio was significantly different between MCI compared to CTRL and AD compared to CTRL. The GO enrichment analysis revealed that two terms (the Biological Process (BP) and Cellular Component (CC) levels) are significantly enriched for NPTXR and Ng but not for VILIP1. Both Ng and NPTXR concentrations in CSF are promising synaptic dysfunction biomarkers for the early diagnosis of the disease. Moreover, both proteins are biochemically associated with classical biomarkers and VILIP-1. Mapping shared molecular and biological functions for the tested proteins by GO enrichment analysis may be beneficial in screening and setting new research targets. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

2. Evaluation of Visinin-Like Protein 1 Concentrations in the Cerebrospinal Fluid of Patients with Mild Cognitive Impairment as a Dynamic Biomarker of Alzheimer's Disease.

Author

Mroczko, Barbara, Groblewska, Magdalena, Zboch, Marzena, Muszyński, Paweł, Zajkowska, Agata, Borawska, Renata, Szmitkowski, Maciej, Kornhuber, Johannes, and Lewczuk, Piotr

Subjects
*ALZHEIMER'S disease research, *BIOMARKERS, *PROTEIN research, *CEREBROSPINAL fluid, *MILD cognitive impairment
Abstract

Background: The correlations between pathology of neurodegenerative diseases, especially Alzheimer's disease (AD), and concentrations of neuronal calcium sensor proteins, such as visinin-like protein 1 (VILIP-1), in cerebrospinal fluid (CSF) have been discussed in the literature but its utility as biomarker of AD in comparison with mild cognitive impairment (MCI) has not been studied yet. Objective: Therefore, the aim of our study was to assess the clinical utility of the measurement of CSF concentrations of VILIP-1 in patients with AD, MCI subjects, and non-demented controls. The clinical and neuropsychological diagnoses were supported by CSF biomarkers of neurochemical dementia diagnostics: decreased concentrations of Aβ1-42 and/or Aβ42/40 ratio and increased concentrations of Tau and pTau181 proteins. Methods: The study included 33 AD patients, 15 subjects with MCI, and 18 elderly individuals without cognitive deficits. The CSF concentrations of biomarkers tested were determined by using the ELISA method. Results: Concentrations of VILIP-1 in CSF were significantly higher in AD patients compared to the MCI subjects and elderly individuals without cognitive impairment. Increased concentrations of VILIP-1 correlated significantly with reduced Aβ42/40 ratio and higher pTau181 in AD group. Conclusion: Our findings suggest that VILIP-1 may play a role in the AD pathophysiology and is a good candidate for dynamic biomarker of AD, although this issue requires further investigation. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

3. Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer’s disease early detection and differential diagnosis in patients with mild cognitive impairment

Author

Goran Šimić, Patrick R. Hof, Nenad Dejanović, Fran Borovečki, and Mirjana Babić Leko

Subjects
Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Statistics as Topic, tau Proteins, Visinin-like protein 1, dementia, biomarker, mild cognitive impairment, Alzheimer’s disease, cerebrospinal fluid, early diagnosis, Diagnosis, Differential, 03 medical and health sciences, 0302 clinical medicine, Cerebrospinal fluid, Alzheimer Disease, Predictive Value of Tests, Internal medicine, medicine, Humans, Dementia, Cognitive Dysfunction, Cognitive decline, Pathological, Aged, Aged, 80 and over, Amyloid beta-Peptides, business.industry, General Neuroscience, General Medicine, Middle Aged, medicine.disease, Peptide Fragments, Psychiatry and Mental health, Clinical Psychology, 030104 developmental biology, ROC Curve, Neurocalcin, Predictive value of tests, Disease Progression, Biomarker (medicine), Female, Geriatrics and Gerontology, Alzheimer's disease, Differential diagnosis, Mental Status Schedule, business, 030217 neurology & neurosurgery
Abstract

Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer's disease (AD). This neuronal calcium sensor protein previously used as a marker of acute ischemic stroke is elevated in the cerebrospinal fluid (CSF) of AD patients. The goal of this study was to assess CSF VILIP-1 potential in early AD diagnosis and in differentiating mild cognitive impairment (MCI) patients with and without risk of AD. Additionally, we tested VILIP-1 ability to differentiate AD from other primary causes of dementia, and predict the progression of AD-related cognitive decline. VILIP-1 levels were compared with five CSF AD biomarkers (t-tau, Aβ1-42, p-tau181, p-tau199, and p-tau231). VILIP-1 successfully differentiated two MCI patient groups characterized by absence or presence of pathological levels of these CSF biomarkers, except for t-tau. VILIP-1/Aβ(1-42) and VILIP-1/p-tau181 ratios also differentiated MCI patients with pathological CSF biomarker levels. However, there was no difference in VILIP-1 levels between AD and MCI patients. VILIP-1/Aβ(1-42) and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and very high specificities (above 85%) in differentiating AD patients from HC. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. VILIP-1 potential as a prognostic biomarker of cognitive decline in AD was also proved since VILIP-1/t-tau, VILIP-1/p-tau181, and VILIP-1/p-tau231 ratios correlated with MMSE scores. These data indicate that VILIP-1 alone or in combination with other AD CSF biomarkers represent a valuable marker for the early diagnosis of AD, recognition of MCI patients at higher risk to develop dementia, and in differentiating AD from LBD.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results